Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crunch Time For Aerie At EMA

An EU Marketing Recommendation Could Be In Store For New Glaucoma Treatment

Executive Summary

Aerie is already exploring its pricing strategy for Roclanda as the European Medicines Agency this week decides whether the intraocular pressure treatment should be approved in Europe.

You may also be interested in...



Phesgo & Roclanda Among New Winners At EMA

The European Medicines Agency this week recommended that five new products be granted EU marketing approval.

No To Five, Yes To Three: NICE Decides On Funding For Drugs In England

Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.

Real World Data In Drug Marketing Applications: Drivers For Success

A study examining 27 drug marketing applications that contained real world data and an idea on how to make it easier for companies to understand which RWD to use were discussed this week at the RAPS EURO Convergence 2021 conference.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel